Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
From Horizon Therapeutics plc
Via Business Wire
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
From Horizon Therapeutics plc
Via Business Wire
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named to the Seramount Inclusion Index
From Horizon Therapeutics plc
Via Business Wire
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
From Horizon Therapeutics plc and Q32 Bio
Via Business Wire
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
From Horizon Therapeutics plc
Via Business Wire
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
From Horizon Therapeutics plc
Via Business Wire
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
From Horizon Therapeutics plc
Via Business Wire
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
From Horizon Therapeutics plc
Via Business Wire
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Horizon Therapeutics plc
Via Business Wire
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.